Asparaginase Wolinella succinogenes-derived - Rare Disease Therapeutics

Drug Profile

Asparaginase Wolinella succinogenes-derived - Rare Disease Therapeutics

Alternative Names: Wolinella succinogenes-derived asparaginase; rWS

Latest Information Update: 01 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Childrens Hospital Los Angeles
  • Class Amidohydrolases; Antineoplastics
  • Mechanism of Action Asparagine modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Sep 2015 Biomarkers information updated
  • 29 Aug 2005 correspondence from RDT 26 Aug 2005. Rewrote intro slightly
  • 21 Jun 2004 Phase-I/II clinical trials in Acute lymphoblastic leukaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top